In individuals with [[glucose-6-phosphate dehydrogenase deficiency]], pegloticase may precipitate a severe, life-threatening [[hemolysis]] with [[methemoglobinemia]]; it is therefore contraindicated in such individuals. Pegloticase may also show [[immunogenicity]].<ref>{{cite book|author=Abraham J. Domb, Neeraj Kumar|title=Biodegradable Polymers in Clinical Use and Clinical Development|url=https://books.google.com/?id=LUOQu6_kLZQC&dq=immunogenicity+Pegloticase|date=2 August 2011|publisher=[[John Wiley & Sons]]|isbn=9781118015803}}</ref>

 

